{"commentary":{"count":118,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":103,"youtube":6,"podcast":6,"x_video":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01730937\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT01730937","nct_id":"NCT01730937","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct01730937. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"400 mg sorafenib twice a day for 28-day cycle. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.","label":"Sorafenib Alone","type":"ACTIVE_COMPARATOR"},{"description":"27.5 Gy to 50 Gy stereotactic body radiation therapy (SBRT) in 5 fractions 24-72 hours apart over 5-15 days followed within 1-5 days by one cycle of 200 mg sorafenib twice a day. Starting with second cycle, if tolerable, increase to 400 mg sorafenib twice a day. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.","label":"SBRT followed by Sorafenib","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)","NRG Oncology"],"completion_date":{"date":"2025-09-04","type":"ACTUAL"},"conditions":["Adult Primary Hepatocellular Carcinoma","Advanced Adult Primary Liver Cancer","Recurrent Adult Primary Liver Cancer"],"enrollment":{"count":193,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Sorafenib","type":"DRUG"},{"name":"stereotactic body radiation therapy","type":"RADIATION"}],"last_update":"2026-01-28","lead_sponsor":"Radiation Therapy Oncology Group","official_title":"Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-07-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"From randomization to last follow-up: weekly during SBRT, post-SBRT/pre-sorafenib, monthly during sorafenib, and overall, from study entry: every 3 months for 2 years, then every 6 months. Maximum follow-up at time of analysis was 7.6 years."}],"references":[{"citation":"Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, Kachnic LA, Gillin MT, Hong TS, Craig TD, Williams TM, Hosni A, Chen E, Noonan AM, Koay EJ, Sinha R, Lock MI, Ohri N, Dorth JA, Delouya G, Swaminath A, Moughan J, Crane CH. Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2025 Feb 1;11(2):136-144. doi: 10.1001/jamaoncol.2024.5403.","pmid":"39699905","type":"DERIVED"}],"start_date":{"date":"2013-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer","url":"https://clinicaltrials.gov/study/NCT01730937"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct01730937"}